| (1R)-Deruxtecan |
|
|
|
|
|
|
|
|
99.32% |
| (Aminooxy)acetamide-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
96.87% |
| (R)-DM4-SPDP |
|
|
|
|
|
|
|
|
|
| (Rac)-Lys-SMCC-DM1 |
|
|
|
|
|
|
|
|
98.58% |
| (S,R,S)-MI-1061 |
|
|
|
|
|
|
|
|
|
| 2',3'-cGAMP-C2-PPA |
|
|
|
|
|
|
|
|
|
| 2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan |
|
|
|
|
|
|
|
|
|
| 2-MSP-2-(pent-4-yn-1-yloxy)acetic acid-VC-PAB-Eribulin |
|
|
|
|
|
|
|
|
97.16% |
| 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan |
|
|
|
|
|
|
|
|
99.39% |
| 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan |
|
|
|
|
|
|
|
|
98.10% |
| 2-MSP-5-HA-VA-PAB-Exatecan |
|
|
|
|
|
|
|
|
97.96% |
| 2-MSP-5-HA-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
98.59% |
| 6-Dehydroxy-demethylation-α-Amanitin-OH-PAB-Ala-Val-CO-C2-mal |
|
|
|
|
|
|
|
|
|
| 7-O-(Amino-PEG4)-paclitaxel |
|
|
|
|
|
|
|
|
98.66% |
| 7-O-(Cbz-N-amido-PEG4)-paclitaxel |
|
|
|
|
|
|
|
|
|
| Ac-Lys-Val-Cit-PABC-MMAE |
|
|
|
|
|
|
|
|
99.94% |
| Ac-Lys-Val-Cit-PABC-MMAE formic |
|
|
|
|
|
|
|
|
99.96% |
| Ac-RKAA-PABC-MMAE |
|
|
|
|
|
|
|
|
|
| Ac-RKAA-PABC-MMAE TFA |
|
|
|
|
|
|
|
|
|
| Acetylene-linker-Val-Cit-PABC-MMAE |
|
|
|
|
|
|
|
|
95.07% |
| Acetylene-PEG3-MMAF-OMe |
|
|
|
|
|
|
|
|
|
| AcLys-PABC-VC-Aur0101 |
|
|
|
|
|
|
|
|
97.17% |
| AcLysValCit-PABC-DMAE-SW-163D |
|
|
|
|
|
|
|
|
|
| ADC 38 drug linker |
|
|
|
|
|
|
|
|
|
| ADC-5 drug-linker |
|
|
|
|
|
|
|
|
|
| ADC-VI |
|
|
|
|
|
|
|
|
|
| AMCC-DM1 |
|
|
|
|
|
|
|
|
|
| Amidate-VC-PAB-MMAF |
|
|
|
|
|
|
|
|
|
| Amine-PEG8-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
|
| Amino-PEG4-GGFG-Dxd |
|
|
|
|
|
|
|
|
99.95% |
| Amino-PEG4-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
99.93% |
| Aminobenzenesulfonic auristatin E |
|
|
|
|
|
|
|
|
|
| Aminobenzenesulfonic auristatin E TFA |
|
|
|
|
|
|
|
|
99.39% |
| Aminobenzenesulfonic auristatin E-d8 |
|
|
|
|
|
|
|
|
98.02% |
| Aminocaproyl-Val-Cit-PABC-Exatecan |
|
|
|
|
|
|
|
|
|
| Aminocaproyl-Val-Cit-PABC-Exatecan TFA |
|
|
|
|
|
|
|
|
99.18% |
| Aminocaproyl-Val-Cit-PABC-MMAE |
|
|
|
|
|
|
|
|
99.89% |
| Aminooxy CatB-LXR |
|
|
|
|
|
|
|
|
|
| AmPEG6C2-Aur0131 |
|
|
|
|
|
|
|
|
|
| Aniline-PEG3-C1-Boc |
|
|
|
|
|
|
|
|
|
| APL-1081 |
|
|
|
|
|
|
|
|
99.79% |
| APL-1082 |
|
|
|
|
|
|
|
|
95.58% |
| APL-1091 |
|
|
|
|
|
|
|
|
|
| APL-1092 |
|
|
|
|
|
|
|
|
|
| APN-PEG5-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
95.19% |
| Asn-Pro-Val-PABC-MMAE TFA |
|
|
|
|
|
|
|
|
|
| ATAC21 |
|
|
|
|
|
|
|
|
|
| AV-DL055 |
|
|
|
|
|
|
|
|
|
| AZ14170133 |
|
|
|
|
|
|
|
|
99.73% |
| AZ14170133-d5 |
|
|
|
|
|
|
|
|
|
| Azide-PEG4-VC-PAB-Doxorubicin |
|
|
|
|
|
|
|
|
99.62% |
| Azido-PEG4-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
99.43% |
| Barzuxetan |
|
|
|
|
|
|
|
|
|
| BAY 1135626 |
|
|
|
|
|
|
|
|
99.19% |
| BCN-HS-PEG2(vcPABC-MMAE)2 |
|
|
|
|
|
|
|
|
99.88% |
| Bi-Mc-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
98.43% |
| Biotin-PEG7-Maleimide |
|
|
|
|
|
|
|
|
99.42% |
| Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide |
|
|
|
|
|
|
|
|
95.59% |
| Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
97.88% |
| BL20-MMAE |
|
|
|
|
|
|
|
|
|
| Boc-Lys-PEG8-N-bis(D-glucose) |
|
|
|
|
|
|
|
|
|
| Boc-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
99.72% |
| Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT |
|
|
|
|
|
|
|
|
98.65% |
| BrAA-glycine-BG-PAB-Exatecan |
|
|
|
|
|
|
|
|
|
| BrAc-Galactose-Sar-N-Me-alanine-DM1 |
|
|
|
|
|
|
|
|
|
| BrAC-GGFG-Aminal-PI3K/mTOR-IN-21 |
|
|
|
|
|
|
|
|
|
| CB07-Exatecan |
|
|
|
|
|
|
|
|
98.97% |
| CCK2R Ligand-Linker Conjugates 1 |
|
|
|
|
|
|
|
|
|
| CL2A-FL118 |
|
|
|
|
|
|
|
|
|
| CL2A-SN-38 |
|
|
|
|
|
|
|
|
99.97% |
| CL2E-SN38 |
|
|
|
|
|
|
|
|
|
| CL2E-SN38 TFA |
|
|
|
|
|
|
|
|
99.26% |
| Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan |
|
|
|
|
|
|
|
|
97.31% |
| Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC |
|
|
|
|
|
|
|
|
|
| Cys-MC-GGFG-Dxd |
|
|
|
|
|
|
|
|
99.01% |
| Cys-MC-GGFG-Dxd-d5 |
|
|
|
|
|
|
|
|
|
| Cys-MC-GGFG-Dxd-d5 TFA |
|
|
|
|
|
|
|
|
|
| Cys-mc-MMAE |
|
|
|
|
|
|
|
|
99.85% |
| Cys-MC-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
98.23% |
| Cys-mcMMAD |
|
|
|
|
|
|
|
|
98.77% |
| DBA-DM4 |
|
|
|
|
|
|
|
|
|
| DBCO-(PEG)3-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
98.35% |
| DBCO-(PEG2-VC-PAB-MMAE)2 |
|
|
|
|
|
|
|
|
99.55% |
| DBCO-HS-PEG2-VA-PABC-SG3199 |
|
|
|
|
|
|
|
|
|
| DBCO-PEG3-GGFG-Exatecan |
|
|
|
|
|
|
|
|
95.65% |
| DBCO-PEG3-Glu-Val-Cit-PABC-MMAE |
|
|
|
|
|
|
|
|
97.69% |
| DBCO-PEG3-Glu-VC-PABC-MMAF |
|
|
|
|
|
|
|
|
|
| DBCO-PEG3-VC-Exatecan |
|
|
|
|
|
|
|
|
96.70% |
| DBCO-PEG4-Ahx-DM1 |
|
|
|
|
|
|
|
|
94.44% |
| DBCO-PEG4-MMAF |
|
|
|
|
|
|
|
|
99.54% |
| DBCO-PEG4-VA-PABC-MMAE |
|
|
|
|
|
|
|
|
98.94% |
| DBCO-PEG4-VA-PBD |
|
|
|
|
|
|
|
|
99.68% |
| DBCO-PEG4-Val-Cit-PAB-MMAF |
|
|
|
|
|
|
|
|
98.05% |
| DBCO-PEG4-VC-PAB-DMEA-PNU-159682 |
|
|
|
|
|
|
|
|
99.03% |
| DBCO-PEG4-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
99.53% |
| DBCO-PEG8-VKG-CPT2 |
|
|
|
|
|
|
|
|
|
| DBCO-tag peptide P1 |
|
|
|
|
|
|
|
|
|
| DBCO-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
95.90% |
| DBCO-β-Glu-PEG12-Exatecan |
|
|
|
|
|
|
|
|
98.63% |
| DBM-C5-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
99.45% |
| DBM-GGFG-NH-O-CO-Exatecan |
|
|
|
|
|
|
|
|
96.83% |
| DBM-MMAF |
|
|
|
|
|
|
|
|
99.65% |
| Demethylation-desulfuration-α-Amanitin-OH-PAB-Ala-Val-CO-C2-mal |
|
|
|
|
|
|
|
|
|
| Deruxtecan |
|
|
|
|
|
|
|
|
99.84% |
| Deruxtecan |
|
|
|
|
|
|
|
|
|
| Deruxtecan analog 2 |
|
|
|
|
|
|
|
|
99.56% |
| Deruxtecan analog 2 monoTFA |
|
|
|
|
|
|
|
|
|
| Deruxtecan-d2 |
|
|
|
|
|
|
|
|
97.45% |
| Deruxtecan-d4 |
|
|
|
|
|
|
|
|
|
| Deruxtecan-d4-1 |
|
|
|
|
|
|
|
|
|
| Deruxtecan-d5 |
|
|
|
|
|
|
|
|
98.40% |
| Deruxtecan-d6 |
|
|
|
|
|
|
|
|
|
| Deruxtecan-Eribulin |
|
|
|
|
|
|
|
|
95.83% |
| Desmethyl Vc-seco-DUBA |
|
|
|
|
|
|
|
|
|
| DGN549-L |
|
|
|
|
|
|
|
|
|
| DIBAC-GGFG-NH2CH2-Dxd |
|
|
|
|
|
|
|
|
98.57% |
| diSPhMC-Asn-Pro-Val-PABC-MMAE |
|
|
|
|
|
|
|
|
|
| DL-01 |
|
|
|
|
|
|
|
|
|
| DL-01 formic |
|
|
|
|
|
|
|
|
98.46% |
| DL-01 TFA |
|
|
|
|
|
|
|
|
|
| DL149 |
|
|
|
|
|
|
|
|
|
| DM1-MCC-PEG3-Biotin |
|
|
|
|
|
|
|
|
|
| DM1-PEG4-DBCO |
|
|
|
|
|
|
|
|
96.11% |
| DM21 |
|
|
|
|
|
|
|
|
99.34% |
| DM21-L-G |
|
|
|
|
|
|
|
|
|
| DM21-L-G NHS ester |
|
|
|
|
|
|
|
|
|
| DM4-SMCC |
|
|
|
|
|
|
|
|
96.86% |
| DM4-SPDP |
|
|
|
|
|
|
|
|
|
| DMBA-SIL-Mal-MMAE |
|
|
|
|
|
|
|
|
|
| DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE |
|
|
|
|
|
|
|
|
|
| Doxorubicin-SMCC |
|
|
|
|
|
|
|
|
98.37% |
| endo-BCN-PEG4-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
98.84% |
| Endo-BCN-PEG4-Val-Cit-PAB-MMAF |
|
|
|
|
|
|
|
|
|
| Exatecan-(D-2,4-DHB)-NH2-AA(bPEG8)-Mal |
|
|
|
|
|
|
|
|
|
| Exatecan-mpGly-Asn-Asn-(βAla) |
|
|
|
|
|
|
|
|
96.25% |
| Exatecan-mpGNNG |
|
|
|
|
|
|
|
|
|
| Fluocinolone acetonide 3-benzylaniline |
|
|
|
|
|
|
|
|
99.93% |
| Fmoc-GGFG-DXd |
|
|
|
|
|
|
|
|
99.81% |
| Fmoc-Gly-Gly-Phe-Gly-Docetaxel |
|
|
|
|
|
|
|
|
|
| Fmoc-Gly-Gly-Phe-Gly-Paclitaxel |
|
|
|
|
|
|
|
|
|
| Fmoc-Gly3-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
|
| Fmoc-NMe-Val-Val-Dil-Dap-OH |
|
|
|
|
|
|
|
|
96.19% |
| Fmoc-Val-Cit-PAB-Duocarmycin TM |
|
|
|
|
|
|
|
|
99.0% |
| Fmoc-Val-Cit-PAB-Exatecan |
|
|
|
|
|
|
|
|
|
| Fmoc-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
98.85% |
| Fmoc-Val-Cit-PAB-MMAF-OtBu |
|
|
|
|
|
|
|
|
|
| Fmoc-Val-Lys(Boc)-PAB-Exatecan |
|
|
|
|
|
|
|
|
|
| Fmoc-VAP-MMAE |
|
|
|
|
|
|
|
|
|
| G3-VC-PAB-DMEA-Duocarmycin DM |
|
|
|
|
|
|
|
|
|
| GDP-Fuc-AM-VcPAB-MMAE |
|
|
|
|
|
|
|
|
|
| Gemcitabine-O-Si(di-iso)-O-Mc |
|
|
|
|
|
|
|
|
98.82% |
| GGFG-amide-glycol-amide-Exatecan |
|
|
|
|
|
|
|
|
95.74% |
| GGFG-Eribulin |
|
|
|
|
|
|
|
|
|
| GGFG-PAB-Exatecan |
|
|
|
|
|
|
|
|
99.71% |
| GGFG-PAB-Exatecan TFA |
|
|
|
|
|
|
|
|
|
| GGFG-PAB-MMAE |
|
|
|
|
|
|
|
|
99.33% |
| GGGDTDTC-Mc-vc-PAB-MMAE |
|
|
|
|
|
|
|
|
99.75% |
| GGGFG-Eribulin |
|
|
|
|
|
|
|
|
|
| Glucocorticoid receptor agonist-1 Ala-Ala-Mal |
|
|
|
|
|
|
|
|
99.91% |
| Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal |
|
|
|
|
|
|
|
|
95.68% |
| Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br |
|
|
|
|
|
|
|
|
98.23% |
| Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal |
|
|
|
|
|
|
|
|
|
| Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br |
|
|
|
|
|
|
|
|
99.67% |
| Glucocorticoid receptor agonist-2 Ala-Ala-Mal |
|
|
|
|
|
|
|
|
97.27% |
| Glucocorticoid receptor agonist-3 Ala-Ala-Mal |
|
|
|
|
|
|
|
|
99.70% |
| Glucocorticoid receptor agonist-4 Ala-Ala-Mal |
|
|
|
|
|
|
|
|
|
| Glucocorticoid receptor drug-linke 1 |
|
|
|
|
|
|
|
|
96.01% |
| Glucocorticoid receptor modulator 4 |
|
|
|
|
|
|
|
|
|
| Gly-Gly-Phe-Gly-NH-O-CO-Exatecan |
|
|
|
|
|
|
|
|
95.91% |
| Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride |
|
|
|
|
|
|
|
|
99.52% |
| Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide |
|
|
|
|
|
|
|
|
99.01% |
| Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan |
|
|
|
|
|
|
|
|
|
| Gly3-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
98.83% |
| GNE-987 GSH linker-2 |
|
|
|
|
|
|
|
|
99.48% |
| HE-S2 |
|
|
|
|
|
|
|
|
|
| HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM |
|
|
|
|
|
|
|
|
|
| Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol |
|
|
|
|
|
|
|
|
98.26% |
| IM-2 |
|
|
|
|
|
|
|
|
|
| L1BC8 |
|
|
|
|
|
|
|
|
99.20% |
| L2-FK866 |
|
|
|
|
|
|
|
|
|
| LD-114 |
|
|
|
|
|
|
|
|
|
| LD-38 |
|
|
|
|
|
|
|
|
|
| Ledadotin |
|
|
|
|
|
|
|
|
|
| LM-D01 |
|
|
|
|
|
|
|
|
|
| LNK2-S |
|
|
|
|
|
|
|
|
96.49% |
| LNK4-S |
|
|
|
|
|
|
|
|
96.41% |
| LP-6 |
|
|
|
|
|
|
|
|
|
| LP-6 TFA |
|
|
|
|
|
|
|
|
|
| LY-22CD |
|
|
|
|
|
|
|
|
|
| Lys-Nε-SPDB-DM4 |
|
|
|
|
|
|
|
|
99.81% |
| Lys-SMCC-DM1 |
|
|
|
|
|
|
|
|
99.25% |
| m-PEG6-Lys-Mal-Toxophore-quinoline |
|
|
|
|
|
|
|
|
|
| m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag |
|
|
|
|
|
|
|
|
|
| MA-PEG4-VC-PAB-DMEA-duocarmycin DM |
|
|
|
|
|
|
|
|
99.84% |
| MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA |
|
|
|
|
|
|
|
|
99.05% |
| mAb-AsnAsn-E104 |
|
|
|
|
|
|
|
|
|
| MAC glucuronide phenol-linked SN-38 |
|
|
|
|
|
|
|
|
99.19% |
| Mal((3S,3aR,6S,6aR)-Hexahydrofuro[3,2-b]furan-3,6-diamine-PEG12)-β-Glu-PAB-Exatecan |
|
|
|
|
|
|
|
|
99.95% |
| Mal-(CH2)5-Val-Cit-PAB-Eribulin |
|
|
|
|
|
|
|
|
99.01% |
| Mal-amido-PEG8-Val-Ala-PAB-SG3200 |
|
|
|
|
|
|
|
|
|
| Mal-Bal-Ph(β-D-Glucose)-7-MAD-MDCPT |
|
|
|
|
|
|
|
|
99.06% |
| Mal-C2-Gly3-EDA-PNU-159682 |
|
|
|
|
|
|
|
|
93.43% |
| Mal-C5-Gly-Gly-Phe-MMAE |
|
|
|
|
|
|
|
|
|
| Mal-C6-α-Amanitin |
|
|
|
|
|
|
|
|
99.83% |
| Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
|
| Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan |
|
|
|
|
|
|
|
|
|
| MAL-di-EG-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
99.92% |
| MAL-di-EG-Val-Cit-PAB-MMAF |
|
|
|
|
|
|
|
|
95.99% |
| Mal-GFLG-TPP-PPA |
|
|
|
|
|
|
|
|
|
| Mal-GGFG-PAB-MMAE |
|
|
|
|
|
|
|
|
99.96% |
| Mal-Gly-PAB-Exatecan-D-glucuronic acid |
|
|
|
|
|
|
|
|
99.82% |
| Mal-N(Me)-C6-N(Me)-PNU-159682 |
|
|
|
|
|
|
|
|
|
| Mal-PEG2-amide-C2-amide-Phenyl(β-D-glucuronide)-NMT-IN-7 |
|
|
|
|
|
|
|
|
95.42% |
| Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan |
|
|
|
|
|
|
|
|
98.62% |
| Mal-PEG2-Val-Arg-PABC-OMe-Eribulin |
|
|
|
|
|
|
|
|
|
| Mal-PEG2-VCP-Eribulin |
|
|
|
|
|
|
|
|
99.79% |
| Mal-PEG4-NPV-PABC-DMEDA-tofacitinib |
|
|
|
|
|
|
|
|
|
| Mal-PEG4-VA-PBD |
|
|
|
|
|
|
|
|
88.94% |
| Mal-PEG4-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
98.00% |
| Mal-PEG4-Val-Cit-PAB-MSA-2 |
|
|
|
|
|
|
|
|
|
| Mal-PEG4-VC-PAB-DMEA-PNU-159682 |
|
|
|
|
|
|
|
|
97.53% |
| Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA |
|
|
|
|
|
|
|
|
|
| Mal-PEG8-Phe-Lys-PAB-Exatecan |
|
|
|
|
|
|
|
|
|
| Mal-PEG8-Phe-Lys-PAB-Exatecan TFA |
|
|
|
|
|
|
|
|
98.66% |
| Mal-PEG8-Val-Ala-Exatecan |
|
|
|
|
|
|
|
|
99.55% |
| Mal-PEG8-Val-Ala-PAB-Exatecan |
|
|
|
|
|
|
|
|
99.48% |
| Mal-PEG8-Val-Ala-PAB-SB-743921 |
|
|
|
|
|
|
|
|
99.28% |
| Mal-PEG8-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
97.12% |
| Mal-PEG8-Val-Cit-PAB-MMAF |
|
|
|
|
|
|
|
|
99.97% |
| Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 |
|
|
|
|
|
|
|
|
|
| Mal-Phe-C4-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
99.54% |
| Mal-PNU-159682 |
|
|
|
|
|
|
|
|
|
| Mal-TLR7 agonist 32 |
|
|
|
|
|
|
|
|
|
| Mal-Toxophore |
|
|
|
|
|
|
|
|
|
| Mal-Val-Ala-amide-(3)PEA-PNU-159682 |
|
|
|
|
|
|
|
|
|
| Mal-Val-Ala-PAB(C2-glucuronic acid)-DMEA-PNU-159682 |
|
|
|
|
|
|
|
|
|
| Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag |
|
|
|
|
|
|
|
|
|
| Mal-Val-Ala-PAB-N(SO2Me)-Exatecan |
|
|
|
|
|
|
|
|
98.84% |
| Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag |
|
|
|
|
|
|
|
|
|
| Mal-Val-Lys-PAB-CBI-PBD dimer |
|
|
|
|
|
|
|
|
|
| Mal-Val-Lys-PAB-MMAE |
|
|
|
|
|
|
|
|
|
| Mal-Val-Lys-PAB-MMAE TFA |
|
|
|
|
|
|
|
|
98.41% |
| Mal-VC-PAB-ABAEP-Azonafide |
|
|
|
|
|
|
|
|
|
| Mal-VC-PAB-DM1 |
|
|
|
|
|
|
|
|
99.41% |
| Mal-VC-PAB-DMEA-PNU-159682 |
|
|
|
|
|
|
|
|
99.36% |
| Mal-VC-PAB-EDA-N-Ac-Calicheamicin |
|
|
|
|
|
|
|
|
|
| Mal-VC-PAB-PNP-CDN-A |
|
|
|
|
|
|
|
|
|
| Mal-VC-PAB-seco-CBI-PBD dimer |
|
|
|
|
|
|
|
|
|
| Maleimide-PEG8-Val-Ala-PAB-SNS032 |
|
|
|
|
|
|
|
|
|
| Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 |
|
|
|
|
|
|
|
|
|
| Maytansine derivative M24 |
|
|
|
|
|
|
|
|
|
| MB-VC-MGBA |
|
|
|
|
|
|
|
|
|
| MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin |
|
|
|
|
|
|
|
|
96.17% |
| MC-AcLys-GDEVD-PABC-Exatecan |
|
|
|
|
|
|
|
|
|
| Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE |
|
|
|
|
|
|
|
|
99.82% |
| MC-Alkyl-Hydrazine Modified MMAF |
|
|
|
|
|
|
|
|
|
| MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 |
|
|
|
|
|
|
|
|
|
| MC-betaglucuronide-MMAE-1 |
|
|
|
|
|
|
|
|
99.23% |
| MC-betaglucuronide-MMAE-2 |
|
|
|
|
|
|
|
|
95.00% |
| MC-cBu-Cit-seco-CBI dimer |
|
|
|
|
|
|
|
|
|
| MC-DM1 |
|
|
|
|
|
|
|
|
99.50% |
| MC-EVCit-PAB-MMAE |
|
|
|
|
|
|
|
|
99.04% |
| MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) |
|
|
|
|
|
|
|
|
95.61% |
| MC-GGFG-3-Methylenecyclobutyl-Exatecan |
|
|
|
|
|
|
|
|
|
| MC-GGFG-AM-(10Me-11F-Camptothecin) |
|
|
|
|
|
|
|
|
98.99% |
| MC-GGFG-AM-(10Me-11F-Camptothecin) intermediate-1 |
|
|
|
|
|
|
|
|
97.47% |
| MC-GGFG-AM-(10NH2-11F-Camptothecin) |
|
|
|
|
|
|
|
|
|
| MC-GGFG-Eribulin |
|
|
|
|
|
|
|
|
|
| MC-GGFG-Exatecan |
|
|
|
|
|
|
|
|
96.47% |
| MC-GGFG-PAB-Exatecan |
|
|
|
|
|
|
|
|
99.31% |
| MC-Gly-Gly-Phe-Exatecan analog 38 |
|
|
|
|
|
|
|
|
|
| MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan |
|
|
|
|
|
|
|
|
97.37% |
| MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan |
|
|
|
|
|
|
|
|
98.99% |
| MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan |
|
|
|
|
|
|
|
|
99.16% |
| MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan |
|
|
|
|
|
|
|
|
99.55% |
| MC-Gly-Gly-Phe-Gly-GABA-Exatecan |
|
|
|
|
|
|
|
|
99.72% |
| MC-Gly-Gly-Phe-Gly-NH-CH2-O-amide-Eribulin |
|
|
|
|
|
|
|
|
|
| MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2CO-homocamptothecin analog |
|
|
|
|
|
|
|
|
|
| MC-Gly-Gly-Phe-Gly-NH-CH2-O-cyclopropane-CH2COOH |
|
|
|
|
|
|
|
|
|
| Mc-Gly-Gly-Phe-Gly-PAB-pSar11-Exatecan |
|
|
|
|
|
|
|
|
|
| Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan |
|
|
|
|
|
|
|
|
|
| Mc-MMAD |
|
|
|
|
|
|
|
|
98.39% |
| Mc-MMAE |
|
|
|
|
|
|
|
|
99.41% |
| Mc-PEG4-Val-Ala-PAB-Exatecan |
|
|
|
|
|
|
|
|
99.65% |
| MC-PEG4-β-Glu-Baloxavir |
|
|
|
|
|
|
|
|
|
| Mc-Phe-Lys-PAB-MMAE |
|
|
|
|
|
|
|
|
|
| Mc-Pro-PAB-MMAE |
|
|
|
|
|
|
|
|
99.16% |
| MC-SN38 |
|
|
|
|
|
|
|
|
99.09% |
| MC-Sq-Cit-PAB-Dolastatin10 |
|
|
|
|
|
|
|
|
|
| MC-Sq-Cit-PAB-Gefitinib |
|
|
|
|
|
|
|
|
|
| MC-VA-PAB-Exatecan |
|
|
|
|
|
|
|
|
98.88% |
| MC-VA-PABC-MMAE |
|
|
|
|
|
|
|
|
99.93% |
| MC-Val-Cit-Doxorubicin |
|
|
|
|
|
|
|
|
99.67% |
| MC-Val-Cit-Gly-exatecan-β-D-glucopyranosiduronic acid |
|
|
|
|
|
|
|
|
|
| MC-Val-Cit-PAB-Auristatin E |
|
|
|
|
|
|
|
|
96.97% |
| MC-Val-Cit-PAB-carfilzomib iodide |
|
|
|
|
|
|
|
|
95.22% |
| MC-Val-Cit-PAB-clindamycin |
|
|
|
|
|
|
|
|
99.99% |
| MC-Val-Cit-PAB-dimethylDNA31 |
|
|
|
|
|
|
|
|
99.58% |
| MC-Val-Cit-PAB-duocarmycin chloride |
|
|
|
|
|
|
|
|
99.04% |
| MC-Val-Cit-PAB-Exatecan |
|
|
|
|
|
|
|
|
99.57% |
| Mc-Val-Cit-PAB-Gefitinib chloride |
|
|
|
|
|
|
|
|
98.69% |
| MC-Val-Cit-PAB-Indibulin |
|
|
|
|
|
|
|
|
96.58% |
| MC-Val-Cit-PAB-Ispinesib |
|
|
|
|
|
|
|
|
99.85% |
| MC-Val-Cit-PAB-MMAF |
|
|
|
|
|
|
|
|
99.25% |
| MC-Val-Cit-PAB-Retapamulin |
|
|
|
|
|
|
|
|
99.37% |
| MC-Val-Cit-PAB-rifabutin |
|
|
|
|
|
|
|
|
95.33% |
| MC-Val-Cit-PAB-vinblastine |
|
|
|
|
|
|
|
|
99.48% |
| MC-VC(S)-PABQ-Tubulysin M |
|
|
|
|
|
|
|
|
|
| MC-VC-PAB-Cyclohexanediamine-Thailanstatin A |
|
|
|
|
|
|
|
|
|
| MC-VC-PAB-Daptomycin |
|
|
|
|
|
|
|
|
|
| MC-VC-PAB-DMEA-PEG2-Duocarmycin SA |
|
|
|
|
|
|
|
|
|
| Mc-VC-PAB-SN38 |
|
|
|
|
|
|
|
|
96.38% |
| MC-VC-PAB-Tubulysin M |
|
|
|
|
|
|
|
|
98.26% |
| MC-VC-PABC-Aur0101 |
|
|
|
|
|
|
|
|
99.70% |
| MC-VC-PABC-C6-α-Amanitin |
|
|
|
|
|
|
|
|
99.62% |
| MC-VC-PABC-DNA31 |
|
|
|
|
|
|
|
|
98.71% |
| MC7 |
|
|
|
|
|
|
|
|
|
| MCC-AAQ-Exa |
|
|
|
|
|
|
|
|
95.33% |
| MCC-DM1 |
|
|
|
|
|
|
|
|
99.52% |
| MCC-Modified Daunorubicinol |
|
|
|
|
|
|
|
|
|
| McMMAF |
|
|
|
|
|
|
|
|
99.97% |
| McMMAF |
|
|
|
|
|
|
|
|
|
| mDPR-Val-Cit-PAB-MMAE TFA |
|
|
|
|
|
|
|
|
98.36% |
| MMAE-PAB(p-glucuronide)-PEG3-aminooxy |
|
|
|
|
|
|
|
|
|
| MMAE-PAB-Gyykr |
|
|
|
|
|
|
|
|
|
| MMAE-SMCC |
|
|
|
|
|
|
|
|
95.65% |
| Modified MMAF-C5-COOH |
|
|
|
|
|
|
|
|
|
| mp-dLAE-PABC-MMAE |
|
|
|
|
|
|
|
|
98.31% |
| MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT |
|
|
|
|
|
|
|
|
98.97% |
| MP-PEG8-Val-Lys-Ala-7-MAD-MDCPT |
|
|
|
|
|
|
|
|
|
| MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT |
|
|
|
|
|
|
|
|
|
| N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(Hexanoyloxy)succinimide-MMAE |
|
|
|
|
|
|
|
|
|
| N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) |
|
|
|
|
|
|
|
|
|
| N-Succinimidyl 3-maleimidopropionate |
|
|
|
|
|
|
|
|
98.53% |
| N3-PEG3-vc-PAB-MMAE |
|
|
|
|
|
|
|
|
99.07% |
| N3-PEG3-VC-PAB-MMAF |
|
|
|
|
|
|
|
|
99.95% |
| N3-PEG8-Phe-Lys-PABC-Gefitinib |
|
|
|
|
|
|
|
|
|
| N3-PEG8-Phe-Lys-PABC-Gefitinib TFA |
|
|
|
|
|
|
|
|
|
| NAMPT inhibitor-linker 1 |
|
|
|
|
|
|
|
|
99.27% |
| NAMPT inhibitor-linker 2 |
|
|
|
|
|
|
|
|
99.35% |
| NH2-Gly-PAB-Exatecan-D-glucuronic acid |
|
|
|
|
|
|
|
|
|
| NH2-Gly-PAB-Exatecan-D-glucuronic acid formic |
|
|
|
|
|
|
|
|
99.34% |
| NH2-PEG3-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
99.10% |
| NHS-MMAF |
|
|
|
|
|
|
|
|
97.20% |
| NHS-Modified MMAF |
|
|
|
|
|
|
|
|
|
| NHS-Modified MMAF TFA |
|
|
|
|
|
|
|
|
96.03% |
| Nitro-PDS-Tubulysin M |
|
|
|
|
|
|
|
|
|
| OBI-992 drug-linker |
|
|
|
|
|
|
|
|
96.64% |
| OH-Glu-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
99.03% |
| OncoFAP-GlyPro-MMAF |
|
|
|
|
|
|
|
|
|
| OSu-Glu-VC-PAB-MMAD |
|
|
|
|
|
|
|
|
|
| OSu-PEG4-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
98.91% |
| OSu-Val-Cit-PAB-Exa |
|
|
|
|
|
|
|
|
|
| P5(PEG12)-VC-PAB-Exatecan |
|
|
|
|
|
|
|
|
|
| P5(PEG24)-VC-PAB-Exatecan |
|
|
|
|
|
|
|
|
|
| Paclitaxel-MVCP |
|
|
|
|
|
|
|
|
|
| PB038 |
|
|
|
|
|
|
|
|
98.99% |
| PB089 |
|
|
|
|
|
|
|
|
99.98% |
| PC5-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
98.91% |
| PC6-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
|
| PDS-MMAE |
|
|
|
|
|
|
|
|
98.56% |
| PEG4-aminooxy-MMAF |
|
|
|
|
|
|
|
|
99.83% |
| PH-HG-005-5 |
|
|
|
|
|
|
|
|
98.34% |
| PNU-EDA-Gly5 |
|
|
|
|
|
|
|
|
|
| Propargyl-PEG4-GGFG-DXd |
|
|
|
|
|
|
|
|
98.69% |
| PSMA-ALB-56 |
|
|
|
|
|
|
|
|
98.92% |
| Puxitatug samrotecan drug-linker |
|
|
|
|
|
|
|
|
98.98% |
| Py-MAA-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
98.46% |
| QHL-1618 |
|
|
|
|
|
|
|
|
|
| Rha-PEG3-SMCC |
|
|
|
|
|
|
|
|
|
| RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide |
|
|
|
|
|
|
|
|
|
| SC-VC-PAB-DM1 |
|
|
|
|
|
|
|
|
93.25% |
| SC-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
99.07% |
| SC239 |
|
|
|
|
|
|
|
|
99.97% |
| SDP-LIV1 drug-linker |
|
|
|
|
|
|
|
|
|
| SG3199-Val-Ala-PAB |
|
|
|
|
|
|
|
|
96.89% |
| SG3376 |
|
|
|
|
|
|
|
|
|
| SG3400 delate(Mal-amido-PEG8) |
|
|
|
|
|
|
|
|
|
| SGD-1910 |
|
|
|
|
|
|
|
|
96.17% |
| SM00465 |
|
|
|
|
|
|
|
|
|
| SMCC-DM1 |
|
|
|
|
|
|
|
|
99.23% |
| SMP-33693 |
|
|
|
|
|
|
|
|
|
| SMP-88480 |
|
|
|
|
|
|
|
|
|
| SMP-93566 |
|
|
|
|
|
|
|
|
|
| SMP-96745 |
|
|
|
|
|
|
|
|
98.99% |
| SN38-COOH |
|
|
|
|
|
|
|
|
98.57% |
| SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 |
|
|
|
|
|
|
|
|
95.08% |
| SPB |
|
|
|
|
|
|
|
|
95.00% |
| SPDB-DM4 |
|
|
|
|
|
|
|
|
99.18% |
| SPP-DM1 |
|
|
|
|
|
|
|
|
96.29% |
| ST8154AA1 |
|
|
|
|
|
|
|
|
|
| ST8155AA1 |
|
|
|
|
|
|
|
|
|
| STING agonist-20-Ala-amide-PEG2-C2-NH2 |
|
|
|
|
|
|
|
|
|
| STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA |
|
|
|
|
|
|
|
|
98.30% |
| STING agonist-49-CO-C2-mal |
|
|
|
|
|
|
|
|
|
| STING agonist-49-PAB-Ala-Val-CO-C2-mal |
|
|
|
|
|
|
|
|
|
| STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal |
|
|
|
|
|
|
|
|
|
| Sulfo-PDBA-DM4 |
|
|
|
|
|
|
|
|
|
| Sulfo-SPDB-DGN462 |
|
|
|
|
|
|
|
|
|
| sulfo-SPDB-DM4 |
|
|
|
|
|
|
|
|
99.81% |
| SuO-Glu-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
99.38% |
| SuO-Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
98.0% |
| TAK-500 drug-linker |
|
|
|
|
|
|
|
|
|
| TAM558 |
|
|
|
|
|
|
|
|
99.48% |
| TCO-PEG3-Glu-Val-Cit-PABC-MMAF |
|
|
|
|
|
|
|
|
|
| TCO-PEG4-VC-PAB-MMAE |
|
|
|
|
|
|
|
|
99.30% |
| Tesirine |
|
|
|
|
|
|
|
|
98.31% |
| Tesirine |
|
|
|
|
|
|
|
|
|
| TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT |
|
|
|
|
|
|
|
|
|
| Thailanstatin A cyclohexane diamine formic |
|
|
|
|
|
|
|
|
93.74% |
| TL033 |
|
|
|
|
|
|
|
|
98.11% |
| TL033 TFA |
|
|
|
|
|
|
|
|
98.06% |
| TLR7 agonist 30 |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 4 hydroxy-PEG10-acid |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride |
|
|
|
|
|
|
|
|
98.28% |
| TLR7/8 agonist 4 hydroxy-PEG6-acid |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride |
|
|
|
|
|
|
|
|
95.54% |
| TUB-010 drug-linker |
|
|
|
|
|
|
|
|
|
| Tub114 |
|
|
|
|
|
|
|
|
|
| Val-Ala-PAB-MMAE |
|
|
|
|
|
|
|
|
99.72% |
| Val-Ala-PAB-SN38 |
|
|
|
|
|
|
|
|
|
| Val-Ala-PAB-SN38 TFA |
|
|
|
|
|
|
|
|
98.22% |
| Val-Ala-PABC-Exatecan |
|
|
|
|
|
|
|
|
99.90% |
| Val-Ala-PABC-Exatecan trifluoroacetate |
|
|
|
|
|
|
|
|
98.39% |
| Val-Ala-PABC-N(Mesylpropane)-Exatecan |
|
|
|
|
|
|
|
|
|
| Val-Cit-amide-Cbz-N(Me)-Maytansine |
|
|
|
|
|
|
|
|
97.92% |
| Val-Cit-amide-Ph-Maytansine |
|
|
|
|
|
|
|
|
98.01% |
| Val-Cit-Exatecan |
|
|
|
|
|
|
|
|
|
| Val-Cit-Exatecan TFA |
|
|
|
|
|
|
|
|
|
| Val-Cit-PAB-DEA-Duo-DM |
|
|
|
|
|
|
|
|
|
| Val-Cit-PAB-DEA-Dxd |
|
|
|
|
|
|
|
|
|
| Val-Cit-PAB-DEA-Dxd TFA |
|
|
|
|
|
|
|
|
99.11% |
| Val-Cit-PAB-Exatecan |
|
|
|
|
|
|
|
|
99.79% |
| Val-Cit-PAB-Exatecan TFA |
|
|
|
|
|
|
|
|
99.73% |
| Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
99.98% |
| Val-Cit-PAB-MMAE |
|
|
|
|
|
|
|
|
|
| Val-Cit-PAB-MMAF |
|
|
|
|
|
|
|
|
|
| Val-Cit-PAB-MMAF sodium |
|
|
|
|
|
|
|
|
98.97% |
| Val-Cit-PABC-DOX |
|
|
|
|
|
|
|
|
|
| Vat-Cit-PAB-Monomethyl Dolastatin 10 |
|
|
|
|
|
|
|
|
|
| Vc-MMAD |
|
|
|
|
|
|
|
|
99.96% |
| Vc-seco-DUBA |
|
|
|
|
|
|
|
|
99.87% |
| VcMMAE |
|
|
|
|
|
|
|
|
|
| VcMMAE |
|
|
|
|
|
|
|
|
99.95% |
| VcMMAE-d8 |
|
|
|
|
|
|
|
|
97.01% |
| VcMMAE-Deruxtecan |
|
|
|
|
|
|
|
|
98.01% |
| VcMMAE-Eribulin |
|
|
|
|
|
|
|
|
98.87% |
| VCP-Eribulin |
|
|
|
|
|
|
|
|
|
| Vipivotide tetraxetan |
|
|
|
|
|
|
|
|
99.46% |
| XB010 drug-linker |
|
|
|
|
|
|
|
|
|
| XMT-1519 conjugate-1 |
|
|
|
|
|
|
|
|
98.07% |
| XMT-1519 conjugate-1 TFA |
|
|
|
|
|
|
|
|
|
| Z52-L16 |
|
|
|
|
|
|
|
|
|
| Z56-L23 |
|
|
|
|
|
|
|
|
|
| β-Glucuronide-dPBD-PEG5-NH2 |
|
|
|
|
|
|
|
|
|
| β-Glucuronide-dPBD-PEG5-NH2 TFA |
|
|
|
|
|
|
|
|
|
| β-Glucuronide-dPBD-PEG6-NH2 |
|
|
|
|
|
|
|
|
|
| β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE |
|
|
|
|
|
|
|
|
|